Is cyclosporine a good option for the treatment of subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic syndrome?
Sir, Subcutaneous panniculitis-like T-cell lymphoma is a rare mature T-cell lymphoma which generally has an indolent clinical behavior. But sometimes it may be associated with hemophagocytic syndrome which leads to a rapidly progressive course. 1 We report a patient with subcutaneous panniculitis-like T-cell lymphoma and secondary hemophagocytic syndrome who responded successfully to oral cyclosporine.
A 26-year-old woman from the Philippines presented with painful, nodular lesions of size ranging from 1 to 3 cm on her limbs, abdomen, and lower back of one month duration.
[ Figure 1a and b].
She had associated high-grade fever and myalgia but no other symptoms like arthralgia. Laboratory tests showed abnormal liver function with elevated aspartate aminotransferase, gamma-glutamyltransferase, alkaline phosphatase, lactate dehydrogenase, and ferritin. Her CD25 was 3588 pg/mL (normal range: 0-1900 pg/mL). Investigations revealed mild anemia, leukopenia, and lymphopenia. An infectious origin was ruled out by performing urine, sputum, stool and blood culture, tuberculin test, tests for antibodies against HBV, HCV, HIV, syphilis, CMV, measles, and EBV in serum, chest and sacroiliac x-ray, and computed tomography scan of chest, abdomen and pelvis. Histopathological examination revealed a dense infiltrate of pleomorphic lymphoid cells with large nuclei and lymphocytoclasia around the adipocytes. There were no pathological changes in dermis and epidermis [ Figure 1c and d]. Lymphocytes expressed CD3, CD8, perforin, and granzyme but not TIA 1 or CD4 [ Figure 1e -h]. Both histopathological and immunohistochemical findings were consistent with subcutaneous panniculitis-like T-cell lymphoma. Bone marrow aspiration cytology showed an increase in the phagocytic mononuclear system with evidence of hemophagocytosis. 18 F-fluorodeoxyglucose positron emission tomography/computed tomography highlighted multiple pathological and generalized uptakes especially over the limbs, abdominal wall, and right breast. Ultrasonography showed splenomegaly. A final diagnosis of subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome was made and the patient was started on oral dexamethasone 12 mg daily. Clinical and biochemical criteria of hemophagocytic syndrome resolved within 1 week, but the patient developed steroid induced hallucinations and amnesia. Hence dexamethasone was withdrawn. Magnetic resonance imaging of brain was normal. Cyclosporine A was initiated at a dose of 125 mg/ day (3 mg/kg of weight) which the patient tolerated and after 6 months of treatment, the dose was tapered gradually. The disease is now well controlled with 25mg/day of cyclosporine A. Table 1 ] with good outcome. 3, 4 One of them was directly started on a combination treatment of cyclosporine A with high doses of prednisolone and had complete resolution, 3 while two patients who had no response with systemic corticosteroids alone achieved complete remission on combining with cyclosporine A. 4, 5 In the remaining patients, cyclosporine A was used after relapse or resistance to chemotherapy or following autologous hematopoietic stem-cell transplantation. 4 Our experience and recently published data suggest that the occurrence of hemophagocytic syndrome does not necessarily mean a more rapidly progressive disease and worse prognosis in all patients with subcutaneous panniculitis-like T-cell lymphoma. Response and long term remission with oral cyclosporine highlights the need to avoid too aggressive therapies. Future prospective studies with large number of patients are necessary to confirm this hypothesis.
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